Search

Displaying results 7811 - 7820 of 10000 in total
  1. Drug

    SPP1148

    go.drugbank.com/drugs/DB05203
    Experimental

    SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.

  2. Drug

    CX157

    go.drugbank.com/drugs/DB05205
    Investigational

    MAO-A inhibitors of this class. … CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous

  3. Drug

    SD118

    go.drugbank.com/drugs/DB05207
    Experimental

    SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy

  4. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated

  5. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    AP1081

    go.drugbank.com/drugs/DB05233
    Experimental

    A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.

  8. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  9. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    MBL forms different oligomers but must form at least a tetramer to be active. … Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains.

  10. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.